Clinical status of carboplatin.
Carboplatin, a cisplatin derivative, shows promise of being an effective weapon against ovarian, cervical, and small-cell lung cancer, as well as epidermoid cancer of the head and neck, with fewer toxic effects than cisplatin. It has successfully completed phase III investigation and clinical trials continue.
Canetta
R
R
Bristol-Myers Company, Pharmaceutical Research and Development Division, Wallingford, Connecticut.
Franks
C
C
Smaldone
L
L
Bragman
K
K
Rozencweig
M
M
D000818:Animals; D000970:Antineoplastic Agents; D016190:Carboplatin; D002460:Cell Line; D002945:Cisplatin / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin; D002945:Cisplatin